BIRMINGHAM, Ala.–(Enterprise WIRE)–CIRCULOGENE, an impressive molecular diagnostics corporation reworking precision drugs as a result of rapid delivery of actionable success, introduced right now that Stephen Unger has joined the enterprise as Main Monetary Officer. Mr. Unger has far more than 25 a long time of economic experience inside of existence sciences by means of senior roles in financial investment banking, community accounting and non-public sector. He earlier served as Main Financial Officer of Quotient Confined, which concluded a productive first community featuring in 2014.
“We are pleased to welcome Stephen to our group and are energized by his eagerness to enable us generate accelerated growth,” said Mike Mullen, CIRCULOGENE President and CEO. “Steve’s wide money administration and money markets expertise in the diagnostics sector, mixed with a track record of corporate finance execution, would make this a ideal fit.”
“I am thrilled to be part of the talented crew of CIRCULOGENE that is plainly making a variation in the life of most cancers clients as a result of the supply of extremely exact and swift diagnostic examination outcomes,” mentioned Stephen Unger. “CIRCULOGENE’s proprietary approach for superior next-era sequencing is unique in the liquid biopsy marketplace, necessitating just one particular 4mL tube to finish a full vary of genomic screening, enabling speedier turnaround periods for most cancers therapy choice, response monitoring, and disorder recurrence assessment.”
Mr. Unger most a short while ago served as a Managing Director of Fairness Investigate at Needham & Business, LLC next the Lifetime Science Resources and Diagnostics sector, where he focused on high-expansion organizations delivering impressive precision medication remedies to fight cancer. Mr. Unger is a Chartered Economical Analyst, a Licensed Community Accountant (inactive) and member of the New York Society of Stability Analysts. He retains a Learn of Company Administration degree from the College of Chicago Booth Faculty of Enterprise and a Bachelor of Business Administration diploma from the University of Wisconsin-Madison.
Transforming precision drugs as a result of swift supply of actionable outcomes, CIRCULOGENE delivers complete biomarker tests for a wide variety of cancers, permitting physicians to match individual effects with particular therapies (or clinical trials) in just 1 week. The firm has designed proprietary next-technology sequencing (NGS) and qPCR procedures that provide a whole genomic load analysis, enabling bigger details precision to assistance clinicians decide on focused therapies, check efficacy and assess recurrence for cancer sufferers. Making use of proprietary liquid biopsy innovation for cfDNA and cfRNA—including PD-L1 and MSI detection— CIRCULOGENE can detect circulating germline and somatic mutations and RNA fusions all from a single 4mL tube of blood, tailoring targeted remedy and immunotherapy devoid of hold off.
CIRCULOGENE is a Scientific Laboratory Advancement Amendments (CLIA) and Faculty of American Pathologists (CAP) accredited laboratory and a Confirmed Seller for the federal Process for Award Management. For far more info, visit our internet site, join with us on LinkedIn, Fb and Twitter, or e-mail us at [email protected] or connect with 855-614-7083. Clinicians interested in ordering assessments may well stop by the Speak to web site on CIRCULOGENE’s web-site.